CGTX
Cognition Therapeutics Inc
NASDAQ · Pharmaceuticals
$1.06
+0.06 (+6.03%)
Income Statement
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 14.30M | 12.78M | 15.45M |
| Net Income | 4.19M | 3.83M | 4.28M |
| EPS | — | — | — |
| Profit Margin | 29.3% | 30.0% | 27.7% |
| Rev Growth | -4.2% | +12.1% | -7.5% |
Balance Sheet
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Total Debt | 29.56M | 25.22M | 24.02M |
| Total Equity | 33.74M | 34.09M | 31.08M |
| D/E Ratio | 0.88 | 0.74 | 0.77 |
Cash Flow
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| EBITDA | 6.72M | 5.55M | 6.77M |
| Free Cash Flow | 3.42M | 2.69M | 4.56M |